An observational study in Heart Valve Diseases, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Heart Valve Diseases with a site in China — 28 open to participants now, 30 under way, none of them phase 3. Heart Valve Diseases · China.
Among the 69 studies in Heart Valve Diseases with a site in China, this one is the 18th largest by planned enrollment of the 35 observational ones that give a count, is one of 7 that started in 2026, is one of 35 observational ones, reaches primary completion later than 14 of the 29 other live ones, and was the 61st registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →28 of the 69 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 200 across the 34 interventional studies, 3,000 across the 35 observational. Of the 18 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 69 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 108 studies on the registry; 73 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Valve Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
| NCT07816146Yongjian Wu, MD, PhDChina Elderly Valve Disease Study III (China-DVD3 Study) | 2026-12-31 |
| NCT03011697Second Affiliated Hospital, School of Medicine, Zhejiang UniversityValvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 69 studies in Heart Valve Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans.
The primary objective is to evaluate the model's diagnostic performance, with the sensitivity serving as the primary efficacy endpoint. Secondary endpoints will include other performance metrics such as area under the receiver operating characteristic curve (AUC), specificity, and accuracy, etc.
This is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans from individuals in any medical context within a hospital alliance.
The primary objective is to evaluate the model's diagnostic performance, with the sensitivity serving as the primary efficacy endpoint. Secondary endpoints will include other performance metrics such as area under the receiver operating characteristic curve (AUC), specificity, and accuracy, etc.
Participants from the target populations will undergo a routine non-contrast chest CT scan. The deep learning model will analyze these images in real-time. For those identified by the model as having moderate-to-severe heart valve disease, a confirmatory echocardiogram will be performed immediately. The echocardiogram results will serve as the reference standard for diagnosis. Statistical analyses will be performed to assess the model's performance against this reference, including calculating the 95% confidence interval for the AUC.
As this study only involves standard, low-radiation diagnostic imaging procedures (non-contrast CT and echocardiography) that are part of routine clinical care, it is considered to pose no additional relevant safety risks to participants. The total study duration is estimated to be 12 months.
People aged 18 and above in any medical context of hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sensitivity
Sensitivity: Measures the proportion of patients with moderate-to-severe disease that the model correctly identifies.
Time frame: 1 year
Area Under the Receiver Operating Characteristic Curve (AUC)
AUC for a model distinguishing valvular disease severity. The AUC value for this model would indicate how well it can correctly identify patients with moderate-to-severe disease from those with normal-to-mild disease.
Time frame: 1 year
Accuracy
Accuracy: Measures the overall proportion of all patients that the model correctly classifies into either group.
Time frame: 1 year
Specificity
Specificity: Measures the proportion of patients with normal-to-mild disease that the model correctly identifies.
Time frame: 1 year
Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 7 months is below that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →